A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

NCT06887192 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Psychosis Associated With Alzheimer's Disease

Interventions

DRUG: ML-007C-MA
DRUG: Placebo

Sponsor

MapLight Therapeutics